RAPS RAC (Devices/Drugs), ACRP/SOCRA, MPJE & ASQ CQE Practice Test
FDA 510(k)/PMA/QMSR/EU MDR device regulation, IND/NDA/BLA & ICH-GCP clinical trials, CSA/DEA & USP / pharmacy law and kinetics, and ASQ CQE/CQA/CRE process capability and reliability.
10 realistic exam questions, graded as you go, with the exact rule or statute citation for every answer. Start free, no sign-up.
Timed mock exam
40 questions in 48 minutes, drawn from every topic. No answers shown until the end, then a full score breakdown, your weakest topics and a review of what you missed.
Prices are in US dollars, plus tax where it applies. Stripe, our payment processor, calculates tax at checkout.
All sales are final. If something is really wrong, such as a duplicate charge or a purchase that does not unlock what you bought, write to support@careerexampro.com and we will put it right.
One-time payment. Nothing renews.
You have an exam ticket for this practice test. Start the timed mock exam to use it.
A medical device manufacturer develops a novel noninvasive optical sensor designed to screen for peripheral arterial disease in outpatient clinics. A thorough search of FDA databases confirms that no legally marketed predicate device exists, yet the company's risk analysis indicates that general and special controls will provide reasonable assurance of safety and effectiveness. Which FDA premarket submission pathway is most appropriate?
A Traditional 510(k) citing a Class II pulse oximeter as a split predicate and proposing bench testing for the new intended use.
A Premarket Approval (PMA) application, because every novel device without a predicate must complete Class III clinical review.
A De Novo classification request to create a new Class I or Class II device type usable as a predicate.
A Humanitarian Device Exemption (HDE), because lacking a legally marketed predicate exempts the sensor from effectiveness evidence.
Show the answer
C. A De Novo classification request to create a new Class I or Class II device type usable as a predicate.
Under FDCA Section 513(f)(2) and 21 CFR Part 860 Subpart D, novel devices lacking a legally marketed predicate are automatically classified into Class III by statute, but low-to-moderate risk devices for which general controls alone (Class I) or general and special controls (Class II) provide reasonable assurance of safety and effectiveness may use the De Novo classification pathway. A granted De Novo creates a new classification regulation and allows the device to serve as a predicate for future 510(k) submissions. Split predicates with different intended uses are not permitted under 510(k), and HDE requires a rare disease/condition affecting fewer than 8,000 individuals per year in the US.
Reference: FDCA § 513(f)(2) / 21 CFR Part 860 Subpart D (De Novo Classification Process)
A retail pharmacy receives a valid Schedule II prescription for 60 tablets of oxycodone 10 mg for an outpatient who is neither terminally ill nor residing in a Long-Term Care Facility (LTCF). Because the pharmacy has only 20 tablets in stock, the pharmacist dispenses 20 tablets on Monday at 10:00 AM after confirming the patient agrees to wait for the remainder. Under federal Controlled Substances Act regulations (21 CFR 1306.13), what rule governs dispensing the remaining 40 tablets?
The remaining 40 tablets may be filled anytime within 30 days of the issue date, matching patient-requested partial fills.
The remaining 40 tablets must be filled within 72 hours, or the prescriber must be notified and the balance voided.
The remaining 40 tablets may be dispensed over multiple increments for up to 60 days from the issue date with prescriber notice.
Federal CSA rules prohibit any partial dispensing of Schedule II prescriptions for out-of-stock shortages, requiring a new order.
Show the answer
B. The remaining 40 tablets must be filled within 72 hours, or the prescriber must be notified and the balance voided.
Under 21 CFR 1306.13(a), when a pharmacy is unable to supply the full quantity of a Schedule II prescription (out of stock), the remaining portion must be supplied within 72 hours of the first partial filling; if the balance cannot be supplied within 72 hours, the pharmacist must notify the prescriber and no further quantity may be supplied without a new prescription. By contrast, patient- or prescriber-requested partial fills under 21 CFR 1306.13(b) (CARA) allow the remainder within 30 days of the issue date, and LTCF or terminally ill patient C-II partial fills are valid for up to 60 days from the issue date.
Reference: 21 CFR 1306.13(a)–(c) (Federal CSA Partial Filling of Schedule II Prescriptions)
On Monday morning, a Class II infusion pump manufacturer becomes aware of a firmware defect across an entire distributed lot that causes unintended rapid bolus delivery, requiring immediate remedial action to prevent an unreasonable risk of substantial harm to the public health. No deaths have been reported yet. Under 21 CFR Part 803 (Medical Device Reporting), what is the mandatory FDA reporting timeline?
Submit an electronic MDR within 30 calendar days, because 5-day reporting applies only after a confirmed fatality.
Submit an electronic 5-day MDR to FDA no later than 5 work days after becoming aware that remedial action is necessary.
Submit a written safety report within 15 calendar days under the expedited timeline governing IND drug applications.
Submit an annual summary MDR report at fiscal year-end, provided a field safety notice is sent to hospitals within 10 business days.
Show the answer
B. Submit an electronic 5-day MDR to FDA no later than 5 work days after becoming aware that remedial action is necessary.
Under 21 CFR 803.53(a), a device manufacturer must submit a 5-day Medical Device Report (MDR) to FDA no later than 5 work days after becoming aware that a reportable event necessitates remedial action to prevent an unreasonable risk of substantial harm to the public health (or after receiving a written FDA request for a 5-day report). Standard death, serious injury, and reportable malfunction MDRs that do not require immediate remedial action are due within 30 calendar days under 21 CFR 803.50.
A hospital pharmacy receives a shipment of high-cost oncology biologics from an authorized wholesale distributor. During receiving verification under the Drug Supply Chain Security Act (DSCSA), the pharmacy technician detects tampered seals and a 2D GS1 DataMatrix product identifier whose serial number does not match the manufacturer's verification database. Subsequent investigation confirms the product is counterfeit (illegitimate). What mandatory DSCSA actions and timelines apply?
Quarantine the vials, notify FDA (Form 3911) and immediate trading partners within 24 hours, and retain records for 6 years.
Return the counterfeit vials to the wholesaler for credit within 72 hours and notify FDA only if a patient receives a dose.
Quarantine the vials, notify FDA within 15 calendar days via MedWatch Form 3500A, and retain transaction records for 2 years.
Destroy the vials immediately using DEA Form 41 to prevent diversion, then file an annual report with the State Board of Pharmacy.
Show the answer
A. Quarantine the vials, notify FDA (Form 3911) and immediate trading partners within 24 hours, and retain records for 6 years.
Under DSCSA (FDCA Section 582), trading partners must verify product identifiers (NDC, serial number, lot number, and expiration date in a 2D DataMatrix barcode) and immediately quarantine any suspect product during investigation. Once a product is determined to be illegitimate (e.g., counterfeit, diverted, or stolen), the dispenser must notify FDA (via Form FDA 3911) and all immediate trading partners that may have received it within 24 hours of making the determination, and must retain investigation and transaction records for at least 6 years.
A medical device manufacturer discovers that a packaging seal defect on a single lot of sterile implantable cardiac leads compromises sterility and creates a reasonable probability of life-threatening endocarditis or death if implanted. The firm initiates a voluntary field removal. How will FDA classify this recall under 21 CFR Part 7, and what Part 806 reporting obligation applies?
Class II recall because the defect affects sterile packaging rather than electrical performance, with no Part 806 report needed.
Class III recall because the firm initiated the removal voluntarily before an FDA order, requiring only an internal CAPA log entry.
Class I recall, with a written 21 CFR 806 report submitted to FDA within 10 working days of initiating the field removal.
Market withdrawal rather than a recall because no patients have developed infection yet, requiring FDA notice within 30 calendar days.
Show the answer
C. Class I recall, with a written 21 CFR 806 report submitted to FDA within 10 working days of initiating the field removal.
Under 21 CFR 7.3(m), a Class I recall applies when there is a reasonable probability that use of or exposure to a violative product will cause serious adverse health consequences or death—a compromised sterile barrier on an implantable cardiac lead clearly meets this threshold. Additionally, under 21 CFR 806.10, a device manufacturer must submit a written report to FDA within 10 working days of initiating any correction or removal conducted to reduce a risk to health posed by the device (unless the same event was already reported under Part 803).